Journal Article

Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration

Ladd, Byron, Singh, Rishi P., Holekamp, Nancy M., Awh, Carl C., Jacobs, Jennifer H., Garfinkel, Richard A., Ho, Allen C., Heier, Jeffrey S., Elman, Michael J., Eichenbaum, David A., Sanborn, George E., Loewenstein, Anat

2021

Overview

The real-world performance of a home telemonitoring strategy (ForeseeHome AMD Monitoring System®, Notal Vision, Inc.,Manassas VA, USA) was evaluated and compared to the device arm of the AREDS2-HOME study among patients with intermediate AMD (iAMD) who converted to neovascular AMD (nAMD). All patients with confirmed conversion to nAMD who used the home monitoring system from 10/2009 through 9/2018 were identified by Notal Vision Diagnostic Clinic’s medical records. Selected outcome variables were evaluated, including visual acuity (VA) at baseline and at conversion, and change in visual acuity (VA) from baseline to time of conversion. In total, 8991 patients performed 3,200,999 tests at a frequency of 5.6 ± 3.2 times/week. The 306 eyes that converted from iAMD to nAMD over the study period (a 2.7% annual rate) were included in the analyses. There was a median (interquartile range) change of −3.0 (0.0–(−10.0)) letters among converted eyes, 81% [95% confidence interval (72–88%)] maintained a VA ≥ 20/40 at the time of conversion, while 69% of the conversion detections were triggered by system alerts. The real-world performance of an at-home testing strategy was similar to that reported for the device arm of the AREDS2-HOME study. The home telemonitoring system can markedly increase early detection of conversion to nAMD.

• Publisher: MDPI AG,MDPI
• Subject: Artificial intelligence / Clinical medicine / Compliance / Conversion / Coronaviruses / COVID-19 / Diabetic retinopathy / Disease transmission / Iris / Macular degeneration / Monitoring systems / Patients / Performance evaluation / Vascular endothelial growth factor